Reason for request
Reassessment
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of BLENREP (belantamab mafodotin) 100 mg, powder for solution for dilution for infusion, is insufficient in the MA indication to justify public funding. |
Clinical Added Value
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
PUjTNSvXfx0x1ctH
